Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent International has announced the treatment of first patient with asymptomatic myeloma (smoldering multiple myeloma) in phase II study of BI-505.
Subscribe to our email newsletter
The study will assess disease activity subsequent to treatment with BI-505 in around 10 patients.
Safety, pharmacokinetics and assessment of biomarkers are the secondary objectives of the study.
BioInvent CEO Cristina Glad said the first study of BI-505 reached the goals.
"The candidate drug was well tolerated and indicated therapeutic effect, since seven of a total of 29 patients with advanced multiple myeloma demonstrated stable disease for at least two months," Glad added.
"The start of this phase II study is another important step forward for BI-505 and we believe that BI-505 has the potential to address a major unmet need in a broad population of patients."
Human antibody BI-505 that binds to the ICAM-1 adhesion protein has orphan drug designation in both Europe and the US for multiple myeloma.